



MANAGEMENT OF *CLOSTRIDIUM DIFFICILE* INFECTION IN PATIENTS WITH IBD

Lawrence J. Brandt, MD

Epidemiologic evidence exists that both colonization and infection with *Clostridium difficile* occur more frequently in patients with inflammatory bowel disease (IBD), especially those with ulcerative colitis (UC), than in the general population. Traditional risk factors for *C. difficile* infection (CDI) do not appear to be offset by the young age of patients with IBD. Risk appears to be augmented by corticosteroid use and the presence of underlying colitis, with its attendant mucosal ulceration and increased colonic permeability.

Symptoms of CDI in patients with IBD may be indistinguishable from those of an IBD flare, and the typical pseudomembrane of CDI is usually absent in IBD patients, making flexible sigmoidoscopy of limited diagnostic use. No guidelines are available for the use of enzyme-linked immunosorbent assay, glutamate dehydrogenase, or nucleic acid amplification tests, such as polymerase chain reaction, to diagnose CDI in patients with IBD. Therefore it is a matter of clinical judgment whether to treat a patient, who has what appears to be an IBD exacerbation, for CDI.

It is a common belief that CDI worsens both the short- and long-term outcomes of IBD, with more frequent emergency department and hospital visits, increased length of stay, greater need for colectomy and increased mortality rates, although supporting data for these conclusions are quite controversial.

Management of CDI in IBD involves several focused clinical decisions, including whether to initiate or discontinue immunosuppressive medication, whether to use conventional or anti-*C. difficile* antimicrobials, and, if so, which ones. Absent data, caution is recommended in beginning or escalating immunosuppression without appropriate antibiotic coverage. There are no universal guidelines for treatment of CDI in patients with IBD, although it seems reasonable to use the same guidelines, based on CDI severity, as recommended for patients without IBD, with a low threshold for treatment escalation. In the absence of data to the contrary, I personally prefer vancomycin and fidaxomicin for patients with IBD. Fecal microbiota transplant for recurrent IBD cannot be recommended outside of a well-designed research protocol.

Selected References

Berg AM, Kelly CP, Farraye FA. *Clostridium difficile* infection in the inflammatory bowel disease patient. *Inflamm Bowel Dis*. 2013;19:194–204.

Ananthakrishnan AN, McGinley EI, Saeian K, Binion DG. Temporal trends in disease outcomes related to *Clostridium difficile* infection in patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2011;17:976–83.

Jodorkovsky D, Young Y, Abreu M. Clinical outcomes of patients with ulcerative colitis and co-existing *Clostridium difficile* infection. *Dig Dis Sci*. 2010;55:415–20.